Skip to main content
Atrás
CASBF logo

CanSino Biologics Inc.

Calidad de datos: 100%
Sobreventa
CASBF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$3.86
$0.00 (0.00%)
Cap. Mercado: 1.35B
Rango del Día
$3.86 $4.10
Rango de 52 Semanas
$3.20 $6.99
Volumen
1,200
Promedio 50D / 200D
$4.29 / $4.91
Cierre Anterior
$3.86

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 49.7 0.3
P/B 0.3 2.9
ROE % 0.5 3.7
Net Margin % 2.6 3.8
Rev Growth 5Y % -29.9 10.0
D/E 0.4 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2028 $3.00
$2.87 – $3.14
2.6 B 1
FY2027 $1.62
$1.54 – $1.69
1.8 B 1
FY2026 $0.98
$0.93 – $1.02
1.5 B 1

Puntos Clave

Revenue declined -29.86% annually over 5 years
ROE of 0.53% is below average
Debt/Equity of 0.41 — conservative balance sheet
Negative free cash flow of -626.43M
P/E of 49.66 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55.98%

Crecimiento

Revenue Growth (5Y)
-29.86%
Revenue (1Y)26.12%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
0.53%
ROIC0.25%
Net Margin2.61%
Op. Margin2.24%

Seguridad

Debt / Equity
0.41
Current Ratio2.42
Interest Coverage0.00

Valoración

P/E Ratio
49.66
P/B Ratio0.27
EV/EBITDA77.49
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 26.12% Revenue Growth (3Y) 73.61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -29.86% Earnings Growth (5Y) -65.49%
Profitability
Revenue (TTM) 1.04B Net Income (TTM) 27.15M
ROE 0.53% ROA 0.34%
Gross Margin 0.00% Operating Margin 2.24%
Net Margin 2.61% Free Cash Flow (TTM) -626.43M
ROIC 0.25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.41 Current Ratio 2.42
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 49.66 P/B Ratio 0.27
P/S Ratio 1.30 PEG Ratio -2.89
EV/EBITDA 77.49 Dividend Yield 0.00%
Market Cap 1.35B Enterprise Value 1.81B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.04B 824.88M 345.18M 1.03B 4.30B
Net Income 27.15M -378.88M -1.48B -909.43M 1.91B
EPS (Diluted) 0.11 -1.53 -6.01 -3.69 7.74
Gross Profit 0.0 580.45M -876.02M -186.61M 3.00B
Operating Income 23.30M -403.39M -2.04B -1.37B 1.94B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 7.96B 9.32B 11.47B 11.87B 6.75B
Total Liabilities 3.05B 4.03B 4.22B 3.33B 677.22M
Shareholders' Equity 4.91B 5.27B 6.75B 8.00B 6.07B
Total Debt 2.01B 2.70B 2.70B 1.37B 142.54M
Cash & Equivalents 1.56B 2.05B 3.39B 5.46B 4.45B
Current Assets 4.28B 5.18B 7.73B 9.29B 5.42B
Current Liabilities 1.77B 2.59B 2.94B 2.87B 412.85M